|
Oct 3
|
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
|
|
Aug 9
|
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
|
|
Aug 8
|
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
|
|
Aug 7
|
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
|
|
Jul 31
|
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
|
|
Jun 20
|
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
|
|
Jun 14
|
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
|
|
Jun 13
|
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
|
|
Jun 12
|
Aldeyra Therapeutics to Host Investor Roundtable Q&A
|
|
May 29
|
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
|
May 14
|
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
|
|
May 8
|
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
|
|
Apr 25
|
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
|
|
Apr 22
|
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
|
|
Apr 18
|
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
|
|
Apr 6
|
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
|
|
Apr 5
|
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
|
|
Apr 4
|
Health Care Roundup: Market Talk
|
|
Apr 3
|
Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval
|
|
Apr 3
|
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner
|